Summary

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by the mitochondrial genome. First described in 2015, it acts on AMPK signalling and skeletal muscle metabolism, earning interest as an 'exercise mimetic' with potential applications in metabolic disease, obesity, and longevity research. Evidence is predominantly preclinical, with early-phase human studies emerging.

Mechanism

MOTS-c activates AMP-activated protein kinase (AMPK) in skeletal muscle, promoting glucose uptake, fatty acid oxidation, and metabolic adaptation. It is encoded by the mitochondrial genome (MT-RNR1), distinguishing it from nuclear-encoded peptides. Its mechanism includes inhibition of the methionine-folate cycle in muscle, leading to AMPK activation, and it functions as a retrograde signalling molecule communicating mitochondrial status to the nucleus.

Evidence base

Evidence is predominantly preclinical. The foundational 2015 study (Lee et al., Cell Metabolism) demonstrated that MOTS-c prevents obesity and insulin resistance in high-fat diet–fed mice. Subsequent animal studies have shown benefits in ageing models, exercise adaptation, and diabetes models. Human evidence is extremely limited: a Phase 1b trial (NCT05522114) of a MOTS-c analogue in obesity has been presented at conferences but full peer-reviewed publication is pending. No Phase 2/3 trials have been completed. The evidence grade is limited.

Protocols

Subcutaneous injection is the most commonly discussed route. Animal studies used 2.5–15 mg/kg doses; research-community discussions reference 5–10 mg per administration, though no validated human dosing exists. Frequency and cycle length are not established. All dosing information is preclinical or anecdotal.

MOTS-c is not a licensed medicine, not a controlled substance, and occupies a UK grey area. It is legal for bona fide research purposes but not approved by the MHRA for any therapeutic use. Vendors label it 'for research purposes only.'

Vendor notes

MOTS-c is stocked by several UK research peptide vendors. Researchers should verify third-party COAs for identity and purity before purchase. See the vendor vetting guide for evaluation criteria.

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.
  2. Lee C, Wan J, Miyazaki B, et al. Mitochondrial-derived peptide MOTS-c is a regulator of plasma membrane and mitochondrial homeostasis. Biochemical and Biophysical Research Communications. 2024.
  3. Lu H, Wei M, Yang Y, et al. MOTS-c ameliorates glucose intolerance and inflammation in type 2 diabetic mice. Life Sciences. 2019;230:157-165.
  4. Lee C, Kim KH, Cohen P. MOTS-c: a novel mitochondrial-derived peptide regulating metabolic homeostasis. BMB Reports. 2016;49(11):571-572.
  5. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2019;10:4405.
  6. ClinicalTrials.gov. NCT05522114. A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MOTS-c analogue in obese participants.